IBRX: financial statements from SEC — TradeAlmanac

IBRX

ImmunityBio, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Dec 31, 2025	Dec 31, 2024
Revenue	113m	15m
Cost of revenue	753,000	0
Research and development	—	190m
Selling, general and administrative	—	169m
Operating expenses	369m	359m
Operating income	−256m	−344m
Pre-tax income	−352m	−414m
Income tax	−135,000	0
Net income	−351m	−414m
Earnings per share	−0.38	−0.59
Earnings per share, diluted	−0.38	−0.62
Weighted average shares	920m	697m
Weighted average shares, diluted	920m	700m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	205m	88m	60m	138m	61m	143m	112m	130m
Short-term investments	176m	154m

Cash flow

Metric	Dec 31, 2025	Dec 31, 2024
Operating cash flow	−305m	−391m
Depreciation and amortisation	16m	18m
Share-based compensation	37m	34m
Capital expenditure	4m	7m
Investing cash flow	−150m	−12m
Financing cash flow	400m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)